PT  - JOURNAL ARTICLE
AU  - Alexander, Lori
ED  - Paré, Guillaume
TI  - Genetic Determinants of Variability in Dabigatran Exposure
DP  - 2012 Nov 01
TA  - MD Conference Express
PG  - 21--22
VI  - 12
IP  - 13
4099  - http://mdc.sagepub.com/content/12/13/21.short
4100  - http://mdc.sagepub.com/content/12/13/21.full
AB  - Genetic factors may be responsible for some of the inter-individual variability in dabigatran exposure, according to findings from the Randomized Evaluation of Long-Term Anticoagulation Therapy [RE-LY] Genetics study. The RE-LY trial demonstrated that dabigatran 150 mg BID was superior to warfarin, while the 110 mg dose was noninferior to warfarin in the reduction of stroke in patients with atrial fibrillation [Connolly SJ et al. N Engl J Med 2009].